![](https://www.pymnts.com/wp-content/uploads/2023/04/Shutterstock_1396957739.jpg)
Amgen and Teva Pharmaceuticals Industries have been granted permission for an expedited appeal in an antitrust case related to Amgen’s Sensipar, a calcium reducer, after a lower court decision.
According to a memorandum by Judge Colm F. Connolly in the US District Court for the District of Delaware, pharmaceutical companies have the right to appeal a decision if he finds that he does not have the authority to allow an interlocutory appeal of a previous judge’s ruling.
Related: Warren Sends Letter To FTC Over Amgen & Indivior Deals
There is “substantial ground for difference of opinion” about whether a judge can certify for interlocutory appeal another judge’s order in the same case, Connolly said.
Featured News
FTC and State Attorneys General Sue John Deere Over Repair Restrictions in Antitrust Case
Jan 15, 2025 by
CPI
Enbridge Wins Legal Battle Against Ducere’s Antitrust Allegations
Jan 15, 2025 by
CPI
GOP Pushes for Antitrust Authority Consolidation Under DOJ in New Legislation
Jan 15, 2025 by
CPI
Canadian Government Approves Bunge-Viterra Merger with Conditions
Jan 15, 2025 by
CPI
SEC Sues Elon Musk Over Delayed Disclosure of Twitter Stock Ownership
Jan 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand